Green Cross sold anti-osteoporosis technology at 160 billion won.

For the first time in the history of Korean Green Cross made a technology transfer of an experimental bio drug "rhPTH (recombinant human parathyroid hormone) to Germany at about 160 billion won (Euro dollar 130 million), the agreement of which was signed at the head office located in Yongin Suji Mokam building with BDD/CCDRD group (representative: Rudolf-Diesbert Alken, MD. Ph.D).

BDD/CCDRD ...